Sugi Predict

Sugi Predict / Compounds / SCHEMBL2017648

SCHEMBL2017648

SCHEMBL2017648

CON(C)C(=O)c1ccnc(Cl)n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PKM P14618 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ ALDH1A1 P00352 3/20 0.36
▸ MAPT P10636 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ CLK1 P49759 1/20 0.35
▸ DYRK1A Q13627 1/20 0.35
▸ DYRK1B Q9Y463 1/20 0.35
▸ TRPM8 Q7Z2W7 2/20 0.35
▸ SLC6A3 Q01959 1/20 0.35
▸ MLYCD O95822 1/20 0.35
▸ CNR2 P34972 1/20 0.33
▸ MEN1 O00255 2/20 0.33
▸ KMT2A Q03164 2/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ TRPV1 Q8NER1 1/20 0.32
▸ LMNA P02545 2/20 0.31
▸ SMN1; SMN2 Q16637 1/20 0.31
▸ TDP1 Q9NUW8 1/20 0.31
▸ GRM4 Q14833 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18824618 0.83 ALDH1A1 (0.39) ALDH1A1MAPTL3MBTL1CNR2MEN1
SCHEMBL29793641 0.82 CLK1 (0.36) PKMRAB9AALDH1A1MAPTL3MBTL1
SCHEMBL17660518 0.82 CLK1 (0.36) PKMRAB9AALDH1A1MAPTL3MBTL1
SCHEMBL25239187 0.81 CLK1 (0.41) PKMRAB9AALDH1A1CLK1DYRK1A
SCHEMBL30307723 0.81 CLK1 (0.41) PKMRAB9AALDH1A1CLK1DYRK1A
SCHEMBL3883174 0.78 SMN1; SMN2 (0.36) L3MBTL1CLK1DYRK1ADYRK1BTRPM8
SCHEMBL4079624 0.77 ALDH1A1 (0.60) PKMRAB9AALDH1A1MAPTL3MBTL1
SCHEMBL4901215 0.77 MLYCD (0.41) CLK1DYRK1ADYRK1BTRPM8MLYCD
SCHEMBL319128 0.76 ALDH1A1 (0.47) RAB9AALDH1A1MAPTL3MBTL1KDM4E
SCHEMBL8374791 0.75 KDM4E (0.45) RAB9AALDH1A1MAPTL3MBTL1CLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11427561-B2 IRAK4 inhibiting agents BIOGEN MA INC. (US) 2022-08-30 — — US disclosed
EP-3405465-B1 IRAK4 INHIBITING AGENTS BIOGEN MA INC (US) 2021-10-13 — — EP disclosed
EP-3405465-B1 IRAK4 INHIBITING AGENTS BIOGEN MA INC (US) 2021-10-13 — — EP disclosed
US-20210188809-A1 IRAK4 INHIBITING AGENTS BIOGEN MA INC. 2021-06-24 — — US disclosed
US-20210188809-A1 IRAK4 INHIBITING AGENTS BIOGEN MA INC. 2021-06-24 — — US disclosed
CN-111108092-A Arylamide Kv2.1 inhibitor and preparation method, pharmaceutical composition and application thereof 中国医学科学院药物研究所 2020-05-05 — — CN disclosed
US-10577367-B2 IRAK4 inhibiting agents BIOGEN MA INC. (US) 2020-03-03 — — US disclosed
US-10577367-B2 IRAK4 inhibiting agents BIOGEN MA INC. (US) 2020-03-03 — — US disclosed
US-20190248787-A1 IRAK4 INHIBITING AGENTS BIOGEN MA INC. 2019-08-15 — — US disclosed
US-20190248787-A1 IRAK4 INHIBITING AGENTS BIOGEN MA INC. 2019-08-15 — — US disclosed
US-20170204093-A1 IRAK4 INHIBITING AGENTS BIOGEN MA INC. 2017-07-20 — — US disclosed
WO-2016011390-A1 IRAK4 INHIBITING AGENTS BIOGEN MA INC. (US) 2016-01-21 — — WO disclosed
WO-2016011390-A1 IRAK4 INHIBITING AGENTS BIOGEN MA INC. (US) 2016-01-21 — — WO disclosed
US-20140243290-A1 Aminopyrimidines as SYK Inhibitors ALTMAN MICHAEL D (US) 2014-08-28 — — US disclosed
US-8759366-B2 Aminopyrimidines as SYK inhibitors MERCK SHARP & DOHME CORP. (US) 2014-06-24 — — US disclosed
US-8551984-B2 Aminopyrimidines as SYK inhibitors MERCK SHARP & DOHME CORP. (US) 2013-10-08 — — US disclosed
US-20120277192-A1 AMINOPYRIMIDINES AS SYK INHIBITORS MERCK SHARP & DOHME LLC 2012-11-01 — — US disclosed
EP-2513098-A1 AMINOPYRIMIDINES AS SYK INHIBITORS Merck Sharp & Dohme Corp. (US) 2012-10-24 — — EP disclosed
US-20110245205-A1 AMINOPYRIMIDINES AS SYK INHIBITORS MERCK SHARP & DOHME LLC 2011-10-06 — — US disclosed
WO-2011075515-A1 AMINOPYRIMIDINES AS SYK INHIBITORS MERCK SHARP & DOHME CORP. (US) 2011-06-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110245205-A1 AMINOPYRIMIDINES AS SYK INHIBITORS SYK, BTK, LCK PKM 1288/4885RAB9A 4273/4885ALDH1A1 1614/4885
US-11427561-B2 IRAK4 inhibiting agents IRAK4, IRAK1, IRAK2 PKM 1562/4885RAB9A 3339/4885ALDH1A1 2209/4885
US-20210188809-A1 IRAK4 INHIBITING AGENTS IRAK4, IRAK1, IRAK2 PKM 1562/4885RAB9A 3339/4885ALDH1A1 2209/4885
US-20140243290-A1 Aminopyrimidines as SYK Inhibitors SYK, BTK, LCK PKM 1288/4885RAB9A 4273/4885ALDH1A1 1614/4885
US-20170204093-A1 IRAK4 INHIBITING AGENTS IRAK4, IRAK1, IRAK2 PKM 1759/4885RAB9A 3499/4885ALDH1A1 3021/4885
US-20190248787-A1 IRAK4 INHIBITING AGENTS IRAK4, IRAK1, IRAK2 PKM 1740/4885RAB9A 3663/4885ALDH1A1 3110/4885
US-20120277192-A1 AMINOPYRIMIDINES AS SYK INHIBITORS SYK, BTK, LCK PKM 1288/4885RAB9A 4273/4885ALDH1A1 1614/4885
US-10577367-B2 IRAK4 inhibiting agents IRAK4, IRAK1, IRAK2 PKM 1740/4885RAB9A 3663/4885ALDH1A1 3110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.